WOX1 Antibody

What is WWOX/WOX1 and what functional roles does it serve in cellular processes?

WWOX (WW domain-containing oxidoreductase), also known as WOX1, functions primarily as a tumor suppressor protein with putative oxidoreductase activity. It plays significant roles in apoptosis (programmed cell death) and is required for normal bone development . When activated through phosphorylation at Tyr33, WOX1 can translocate to mitochondria and nuclei to induce apoptosis both in vitro and in vivo .

WWOX participates in several important signaling pathways, including TGFB1 signaling and TGFB1-mediated cell death, tumor necrosis factor (TNF)-mediated cell death, and inhibition of Wnt signaling by sequestering DVL2 in the cytoplasm . Additionally, WWOX may function synergistically with p53/TP53 to control genotoxic stress-induced cell death. These diverse functions highlight the importance of reliable antibodies for studying this multifunctional protein.

What types of WOX1 antibodies are available for research applications?

Researchers have access to several types of WOX1/WWOX antibodies, each with specific advantages for different applications:

• Polyclonal antibodies: These recognize multiple epitopes of WWOX and provide high sensitivity. Examples include sheep anti-human/mouse/rat WWOX antigen affinity-purified polyclonal antibody .

• Monoclonal antibodies: These target specific epitopes with high specificity and consistency between batches, suitable for applications requiring reproducibility.

• Phospho-specific antibodies: These recognize WWOX specifically when phosphorylated at Tyr33 (phospho Y33), which is critical for its activation and pro-apoptotic function .

• Recombinant antibodies: Generated through molecular cloning, these offer the highest consistency and reproducibility between batches. Research indicates that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies across multiple assays .

The choice between these antibody types should be guided by your specific research questions, applications, and the need for detecting specific modifications or forms of WWOX.

What are the validated applications for WOX1 antibodies in research protocols?

WOX1 antibodies have been validated for multiple research applications with specific considerations for each:

• Western blotting (WB): WWOX antibodies detect the protein (predicted molecular weight of 47 kDa) in cell or tissue lysates . Commercial antibodies are typically validated with cell lines including Jurkat (human), Balb/3T3 (mouse), and L6 (rat) . Optimal antibody dilutions range from 1/500 to 1/50 depending on the specific antibody and sample .

• Immunohistochemistry on paraffin-embedded tissues (IHC-P): Antibodies like phospho-Y33 WWOX antibodies have been validated for detecting WWOX in tissues like human colon carcinoma . Typical dilutions range from 1/50 for phospho-specific antibodies .

• Co-immunoprecipitation: WWOX antibodies effectively precipitate protein complexes, allowing study of interactions such as the WWOX/MEK1 complex. This application has been crucial in identifying how stimuli like PMA affect WWOX interactions .

• Immunofluorescence: Antibodies can be used to examine subcellular localization and translocation during processes like apoptosis, particularly when studying WWOX activation.

When selecting antibodies, verify that they have been specifically validated for your intended application and biological system to ensure reliable results.

What strategies should researchers employ to verify WOX1 antibody specificity?

Verifying antibody specificity is critical for ensuring reliable research results. For WOX1 antibodies, implement these validation strategies:

• Knockout (KO) cell line controls: These represent the gold standard for antibody validation. Recent comprehensive research demonstrates that KO cell lines are superior to other types of controls, especially for Western blots and immunofluorescence imaging .

• Peptide competition/blocking: Pre-incubating the antibody with the immunizing peptide should abolish specific signals. This approach is particularly valuable for phospho-specific antibodies, where staining can be eliminated using the corresponding phosphopeptide .

• RNA interference: Knockdown WWOX using siRNA (WOX1si) and verify decreased antibody signal proportional to knockdown efficiency .

• Multiple antibodies approach: Use antibodies targeting different WWOX epitopes and compare detection patterns to confirm specific recognition.

• Positive controls: Include samples known to express WWOX, such as Jurkat, Balb/3T3, or L6 cell lines, to verify appropriate detection .

A shocking study revealed that an average of ~12 publications per protein target included data from antibodies that failed to recognize the relevant target protein , highlighting the critical importance of proper antibody validation.

What cross-species reactivity considerations apply when selecting WOX1 antibodies?

When selecting WOX1 antibodies for cross-species applications, consider these important factors:

• Documented cross-reactivity: Many commercial WWOX antibodies react with human, mouse, and rat WWOX due to high sequence homology. Look for antibodies explicitly tested in multiple species, such as those validated by Western blot against Jurkat (human), Balb/3T3 (mouse), and L6 (rat) cell lines .

• Epitope conservation: Verify if the antibody's target epitope is conserved across your species of interest. Some antibodies recognize the N-terminal amino acid sequence or specific domains that may show different degrees of conservation .

• Application-specific cross-reactivity: An antibody might work in one species for Western blot but not for immunohistochemistry. Check validation data for your specific application in your species of interest.

• Isoform recognition: Different species may express different WWOX isoforms. Ensure the antibody recognizes the isoform present in your experimental system.

• Validation strength: Antibodies with pan-specific reactivity against human, mouse, and rat WWOX have been generated using specific sequences and validated through multiple approaches , providing greater confidence in cross-species applications.

How does Tyr33 phosphorylation regulate WOX1 function, and how can researchers detect this modification?

Tyr33 phosphorylation serves as a critical regulatory mechanism for WOX1 activation and function:

• Functional significance: When phosphorylated at Tyr33, WOX1 becomes activated, enabling its translocation to mitochondria and nuclei where it induces apoptosis both in vitro and in vivo . This phosphorylation event is therefore a key molecular switch in WOX1's pro-apoptotic function.

• Detection methods:

  • Phospho-specific antibodies: Antibodies specifically recognizing phosphorylated Tyr33 (such as rabbit polyclonal antibody ab129881) allow direct detection of activated WWOX .

  • Applications: These antibodies work in Western blotting (typically at 1/500 dilution) and immunohistochemistry (at 1/50 dilution) .

  • Controls: Specificity can be verified using competing phosphopeptides, which should eliminate detection signal .

• Experimental considerations:

  • When studying phosphorylated WWOX, samples must be prepared with phosphatase inhibitors to preserve the modification.

  • PMA treatment (10 μM) of Jurkat cells can serve as a positive control for WOX1 activation .

  • Dominant negative WOX1 constructs with mutations preventing Tyr33 phosphorylation can serve as valuable negative controls .

• Signaling context: Tyr33 phosphorylation status affects WWOX's interaction with other proteins, including MEK1. PMA treatment rapidly dissociates the WOX1/MEK1 complex in Jurkat cells but not in Molt-4 cells, correlating with differential apoptotic responses .

What are the essential controls for experiments utilizing WOX1 antibodies?

Implementing appropriate controls is critical for reliable WOX1 antibody-based experiments:

• Negative controls:

  • Knockout cell lines: WWOX knockout cells provide the most definitive negative control. Research demonstrates they are superior to other control types, particularly for Western blots and immunofluorescence imaging .

  • siRNA knockdown samples: Cells treated with WWOX-specific siRNA (WOX1si) show reduced antibody signal proportional to knockdown efficiency .

  • Peptide competition: Pre-incubating antibody with immunizing peptide should eliminate specific signal .

• Positive controls:

  • Known WWOX-expressing cell lines: Jurkat, Balb/3T3, and L6 cell lines are documented to express detectable WWOX .

  • WWOX-overexpressing cells: Cells transfected with WWOX expression constructs provide strong positive signals.

  • Stimulated samples: For phospho-specific detection, include samples treated with stimuli known to induce phosphorylation.

• Treatment validation controls:

  • MEK inhibition: U0126 treatment prevents PMA-mediated dissociation of the WOX1/MEK1 complex, serving as a pathway validation control .

  • Phosphatase treatment: For phospho-antibodies, include phosphatase-treated samples to confirm phospho-specificity.

• Antibody controls:

  • Non-immune sera: Include non-immune sera in immunoprecipitation experiments to identify non-specific binding .

  • Isotype controls: Use non-specific antibodies of the same isotype to identify non-specific binding.

  • Secondary antibody-only: Omit primary antibody to identify background from secondary antibody.

How should researchers optimize immunohistochemical detection of WOX1 in different tissue types?

Optimizing immunohistochemical detection of WWOX requires consideration of multiple variables:

• Tissue fixation and processing:

  • Most commercial WWOX antibodies are validated for formalin-fixed, paraffin-embedded (FFPE) tissues .

  • Optimal fixation time in 10% neutral buffered formalin is typically 24-48 hours.

  • For phospho-epitopes like phospho-Y33 WWOX, rapid fixation helps preserve phosphorylation status.

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is commonly effective for WWOX detection.

  • For phospho-Y33 WWOX, EDTA buffer (pH 9.0) may better preserve phospho-epitopes.

  • Optimization of retrieval conditions is crucial, as excessive retrieval can damage tissue morphology while insufficient retrieval results in weak signal.

• Antibody concentration and incubation:

  • Titrate antibody concentration for each tissue type (starting recommendations: 1/50 for phospho-Y33 WWOX in IHC-P) .

  • Optimize incubation time and temperature (typically overnight at 4°C or 1-2 hours at room temperature).

  • Consider signal amplification systems for low-expression tissues.

• Detection systems:

  • For chromogenic detection, DAB (3,3'-diaminobenzidine) is commonly used.

  • For fluorescent detection, select fluorophores with minimal spectral overlap when multiplexing.

  • When examining colocalization, choose fluorophores with appropriate spectral separation.

• Validation in each tissue type:

  • Include known positive and negative control tissues.

  • For phospho-Y33 WWOX, include competing phosphopeptide controls to verify specificity .

  • Consider dual staining approaches to correlate WWOX with functional markers.

What advantages do recombinant WOX1 antibodies offer over traditional antibody types?

Recombinant WOX1 antibodies provide several significant advantages over traditional antibody types:

• Superior performance: Comprehensive studies demonstrate that recombinant antibodies outperform both monoclonal and polyclonal antibodies across multiple assay types on average . This translates to more reliable and reproducible results in WWOX research.

• Batch-to-batch consistency: Unlike polyclonal antibodies that vary between animals and bleeds, or monoclonal antibodies that can drift during hybridoma culture, recombinant antibodies are produced from defined DNA sequences, ensuring consistent performance over time.

• Renewable source: The DNA sequence encoding recombinant antibodies can be stored indefinitely and expressed when needed, eliminating concerns about hybridoma stability or animal availability.

• Definable properties: Recombinant antibodies can be precisely engineered to:

  • Improve affinity for specific WWOX epitopes

  • Alter species cross-reactivity

  • Add tags for detection or purification

  • Modify format for specific applications (e.g., Fab, scFv)

• Sequence transparency: Complete sequence information enables better understanding of binding properties, easier troubleshooting, and potential for further optimization.

• Ethical considerations: Recombinant antibody production reduces or eliminates the need for animals in antibody generation, aligning with efforts to reduce animal use in research.

These advantages make recombinant antibodies an increasingly preferred option for WWOX research, particularly for studies requiring high reproducibility and consistent performance.

What are the key parameters for optimizing Western blot protocols for WOX1 detection?

Optimizing Western blot protocols for reliable WWOX detection requires attention to several critical parameters:

• Sample preparation:

  • Lysis buffers: RIPA buffer with protease inhibitors works well for general WWOX detection.

  • For phospho-WWOX: Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride) to preserve phosphorylation at Tyr33.

  • Treatment conditions: For studying WOX1/MEK1 interactions, PMA treatment (10 μM) can be used to dissociate this complex in Jurkat cells .

• Gel electrophoresis parameters:

  • Expected size: WWOX has a predicted molecular weight of 47 kDa .

  • Gel percentage: 10-12% SDS-PAGE gels typically provide good resolution.

  • Loading controls: Use appropriate loading controls (β-actin, GAPDH, α-tubulin) for normalization .

• Transfer conditions:

  • Membrane type: PVDF membranes are commonly used for WWOX detection with good results .

  • Transfer method: Semi-dry or wet transfer at appropriate voltage (typically 100V for 1 hour or 30V overnight).

  • Transfer verification: Use reversible staining to confirm protein transfer.

• Antibody incubation optimization:

  • Primary antibody dilution: Typical working dilutions range from 1/500 for phospho-Y33 antibodies to 0.5 μg/mL for some commercial antibodies .

  • Incubation conditions: Typically 1-2 hours at room temperature or overnight at 4°C in appropriate blocking buffer.

  • Secondary antibody: Choose appropriate host species and detection system (HRP is common).

• Detection and analysis:

  • Enhanced chemiluminescence (ECL): Standard for most WWOX Western blots.

  • Exposure optimization: Capture multiple exposures to ensure signal is in linear range.

  • Quantification: Use appropriate software for densitometric analysis.

• Positive controls:

  • Include lysates from cell lines known to express WWOX, such as Jurkat, Balb/3T3, or L6 cell lines .

  • For phospho-WWOX, include samples treated with PMA or other activating stimuli .

What methodological approaches can uncover the regulatory dynamics of the WOX1/MEK1 interaction?

Studying the WOX1/MEK1 interaction and its regulation by PMA requires sophisticated methodological approaches:

• Co-immunoprecipitation strategies:

  • Cell model selection: Jurkat and Molt-4 T cells show differential responses to PMA, making them valuable comparative models .

  • Treatment protocol: Expose cells to PMA (10 μM) for varying durations (10 minutes for Jurkat cells shows rapid complex dissociation) .

  • Mechanistic dissection: Pretreat with U0126 (MEK inhibitor) before PMA exposure to investigate pathway dependencies .

  • Reciprocal co-IP: Perform immunoprecipitation with both anti-WOX1 and anti-MEK1 antibodies to confirm interaction.

  • Controls: Include non-immune sera controls to verify specificity of immunoprecipitation .

• Temporal dynamics analysis:

  • Time course design: Treat cells with PMA for incremental durations (0-60 minutes).

  • Parallel tracking: Simultaneously monitor complex dissociation and WWOX Tyr33 phosphorylation.

  • Kinetic modeling: Analyze the temporal relationship between phosphorylation and complex dissociation.

• Cellular response correlation:

  • Cell type comparison: Jurkat cells show rapid dissociation of WOX1/MEK1 complex upon PMA treatment, while Molt-4 cells do not, correlating with differential apoptotic responses .

  • Functional readouts: Correlate complex dynamics with DNA fragmentation and cell cycle analysis .

  • Signaling pathway integration: Monitor ERK phosphorylation status in relation to WOX1/MEK1 complex dynamics .

• Genetic manipulation approaches:

  • Dominant negative strategy: Express DN-WOX1 constructs (with mutations at Lys28/Asp29) to block WOX1 activation .

  • Domain mapping: Express the isolated WW domain (WOX1ww) to identify minimal interaction regions .

  • Knockdown validation: Use WOX1si to confirm role of endogenous WWOX in observed phenomena .

• Visualization techniques:

  • Proximity ligation assay: Visualize WOX1/MEK1 interaction in situ and its disruption by PMA.

  • FRET analysis: Monitor real-time interaction dynamics using fluorescently tagged proteins.

  • Live cell imaging: Track translocation events following complex dissociation.

How can researchers design comprehensive studies of WOX1's role in apoptotic pathways?

Investigating WOX1's role in apoptosis requires multifaceted experimental approaches:

• Apoptosis induction and WOX1 activation analysis:

  • Stimuli selection: PMA treatment (10 μM) reliably induces apoptosis in Jurkat cells .

  • Activation monitoring: Track Tyr33 phosphorylation using phospho-specific antibodies .

  • Temporal correlation: Create a timeline correlating WOX1 activation with apoptotic markers.

  • Multi-parameter analysis: Simultaneously monitor DNA fragmentation, cell cycle changes, and WOX1 activation .

• Genetic manipulation strategies:

  • Gain-of-function approach: Transiently overexpress WOX1 or its N-terminal WW domain (WOX1ww) to enhance PMA-induced apoptosis .

  • Loss-of-function approach: Express dominant negative WOX1 (DN-WOX1) to inhibit PMA-induced apoptosis and ERK phosphorylation .

  • RNA interference: Use WOX1si to knockdown expression and assess effects on apoptotic response .

  • Controls: Include appropriate vector-only controls (e.g., EGFP alone) to distinguish construct-specific effects .

• Signaling pathway integration:

  • MEK/ERK pathway: Use U0126 to inhibit MEK and assess effects on WOX1-mediated apoptosis .

  • p53 pathway: Investigate synergistic effects between WOX1 and p53 in genotoxic stress response .

  • Death receptor pathways: Examine WOX1's role in TNF-mediated cell death .

  • TGFB1 signaling: Analyze WOX1's contribution to TGFB1-mediated apoptosis .

• Subcellular localization studies:

  • Fractionation approach: Separate nuclear, mitochondrial, and cytoplasmic fractions followed by Western blotting.

  • Immunofluorescence: Track WOX1 translocation during apoptosis using confocal microscopy.

  • Co-localization analysis: Examine WOX1 association with mitochondria or nuclear compartments during apoptosis.

• Comprehensive apoptosis readouts:

  • DNA fragmentation: Quantify internucleosomal DNA cleavage as a late apoptotic marker .

  • Phosphatidylserine exposure: Measure Annexin V binding as an early apoptotic marker.

  • Caspase activation: Determine the relationship between WOX1 activation and caspase pathway activation.

  • Mitochondrial membrane potential: Monitor mitochondrial integrity in relation to WOX1 activation.

What specialized techniques can track WOX1's dynamic subcellular localization during apoptosis?

Tracking WOX1's dynamic subcellular localization during apoptosis requires sophisticated imaging and biochemical approaches:

• Advanced microscopy techniques:

  • Confocal microscopy: Achieve high-resolution optical sectioning to precisely locate WOX1 within cellular compartments.

  • Live cell imaging: Monitor real-time translocation of fluorescently tagged WOX1 during apoptosis progression.

  • Super-resolution microscopy: Use techniques like STORM or STED to visualize WOX1 localization at nanoscale resolution.

  • Multi-color imaging: Simultaneously track WOX1 and organelle markers or apoptotic machinery components.

• Biochemical fractionation approaches:

  • Differential centrifugation: Isolate nuclear, mitochondrial, cytoplasmic, and membrane fractions.

  • Density gradient separation: Achieve higher resolution separation of organelles.

  • Western blot analysis: Probe fractions with both total WWOX and phospho-Y33 WWOX antibodies .

  • Purity controls: Verify fraction quality using organelle-specific markers (e.g., VDAC for mitochondria, Lamin B for nucleus).

• Temporal dynamics analysis:

  • Time-course design: Fix cells at precise intervals after apoptotic stimulus.

  • Synchronized populations: Use cell cycle synchronization to reduce cell-to-cell variability.

  • Pulse-chase approaches: Label WWOX or interacting proteins to track movement between compartments.

  • Sequential sampling: Create a comprehensive timeline of translocation events.

• Proximity-based detection methods:

  • Proximity ligation assay (PLA): Visualize interactions between WOX1 and compartment-specific proteins in situ.

  • FRET/BRET analysis: Measure real-time protein-protein interactions and conformational changes.

  • BiFC (Bimolecular Fluorescence Complementation): Visualize protein complex formation in living cells.

• Correlative approaches:

  • Combined immunofluorescence and functional assays: Correlate WOX1 localization with markers of mitochondrial permeabilization or nuclear condensation.

  • Single-cell analysis: Correlate WOX1 localization patterns with apoptotic progression at the individual cell level.

  • Multi-parametric flow cytometry: Simultaneously measure WOX1 activation state and apoptotic markers in large cell populations.

What strategies can overcome challenges in WOX1 detection across diverse biological samples?

Detecting WOX1 across diverse biological samples presents several challenges requiring specialized approaches:

• Low expression level strategies:

  • Signal amplification systems: Use tyramide signal amplification or similar techniques for IHC and IF applications.

  • Enrichment approaches: Employ immunoprecipitation before Western blotting for low-abundance samples.

  • Sensitive detection reagents: Utilize high-sensitivity ECL substrates for Western blots.

  • Extended exposure times: Optimize detection without introducing background.

• Isoform and modification-specific detection:

  • Antibody panel approach: Use multiple antibodies targeting different WWOX domains to detect various isoforms.

  • Phospho-specific antibodies: Employ phospho-Y33 specific antibodies to detect activated WWOX .

  • Dephosphorylation controls: Include phosphatase-treated samples to confirm phospho-specificity.

  • 2D gel electrophoresis: Separate WWOX isoforms and post-translationally modified forms before Western blotting.

• Tissue-specific optimization:

  • Fixation protocol customization: Optimize fixative type, concentration, and duration for each tissue type.

  • Antigen retrieval optimization: Determine optimal retrieval method (heat vs. enzymatic) and buffer composition for each tissue.

  • Block optimization: Test various blocking agents to minimize background in high-background tissues.

  • Antibody titration: Determine optimal concentration for each sample type.

• Species cross-reactivity solutions:

  • Epitope mapping: Identify antibodies targeting highly conserved regions for cross-species applications.

  • Species-specific positive controls: Include known WWOX-expressing samples from each species studied.

  • Sequence comparison: Analyze epitope conservation across species before antibody selection.

  • Validation hierarchy: Prioritize antibodies explicitly validated in your species of interest.

• Quality control measures:

  • Knockout validation: Use WWOX knockout tissues/cells as definitive negative controls .

  • Recombinant antibody advantage: Consider recombinant antibodies which typically outperform other types in reproducibility .

  • Multiple detection methods: Confirm findings using independent techniques (e.g., Western blot, IHC, IF).

  • Independent antibody verification: Use antibodies from different sources targeting different epitopes.

How should researchers interpret results when using dominant negative WOX1 constructs?

Interpreting results from dominant negative WOX1 (DN-WOX1) experiments requires careful consideration of several factors:

• Construct design and mechanism:

  • Key mutations: DN-WOX1 constructs typically contain alterations at Lys28 and Asp29 to Thr28 and Val29 in the first WW domain .

  • Functional mechanism: These mutations prevent Tyr33 phosphorylation, blocking WOX1 activation and subsequent pro-apoptotic function.

  • Available variants: Both full-length DN-WOX1 and WW domain-only (DN-WOX1ww) constructs provide different levels of inhibition .

• Expression verification protocols:

  • Direct visualization: Most constructs are EGFP-tagged, allowing fluorescence microscopy confirmation .

  • Western blot analysis: Detect tagged constructs using both anti-WWOX and anti-tag antibodies.

  • Consistent expression: Ensure comparable expression levels between wild-type and DN-WOX1 constructs for valid comparisons.

  • Temporal stability: Monitor expression over time in transient transfection experiments.

• Functional readout interpretation:

  • Apoptosis inhibition: DN-WOX1 inhibits PMA-induced apoptosis in Jurkat T cells .

  • Signaling pathway effects: DN-WOX1 inhibits PMA-induced ERK phosphorylation .

  • Mechanism insights: Effects confirm the requirement for Tyr33 phosphorylation in WOX1's pro-apoptotic function.

  • Cell-type specificity: Compare effects between sensitive cells (Jurkat) and resistant cells (Molt-4) .

• Control considerations:

  • Empty vector controls: Always include vector-only controls (e.g., EGFP alone) to distinguish construct effects from transfection effects .

  • Wild-type overexpression: Compare with wild-type WOX1 overexpression to distinguish dominant negative versus overexpression effects .

  • Dose-response relationship: Test multiple expression levels to determine threshold effects.

  • Transfection efficiency normalization: Account for differences in transfection efficiency between constructs.

• Complementary approaches:

  • siRNA validation: Confirm findings using WOX1si knockdown approaches .

  • Pharmacological inhibitors: Combine with pathway inhibitors (e.g., U0126 for MEK) to confirm mechanism .

  • Rescue experiments: Attempt to rescue DN-WOX1 effects with constitutively active downstream effectors.

  • In vivo validation: When possible, confirm findings in animal models expressing DN-WOX1.